Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive pulmonary disease (COPD). METHODS: In a phase 3, double-blind, randomized, placebo-controlled trial, patients with COPD, a history of exacerbations, and a blood eosinophil count of at least 300 cells per microliter who were receiving triple inhaled therapy were assigned, in a 1:1 ratio, to receive mepolizumab (at a dose of 100 mg) or placebo subcutaneously every 4 weeks for 52 to 104 weeks. The primary end point was the annualized rate of moderate or severe exacerbations. Secondary end points, tested hierarchically to control for multiplicity, were moderate or severe exacerbation as assessed in a time-to-first-event analysis, measures of health-related quality of life and symptoms, and the annualized rate of exacerbations leading to an emergency department visit, hospitalization, or both. RESULTS: Of the 804 patients who underwent randomization, 403 were assigned to receive mepolizumab and 401 to receive placebo. The annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than with placebo (0.80 vs. 1.01 events per year; rate ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.01). The time to the first moderate or severe exacerbation was longer with mepolizumab than with placebo (Kaplan-Meier median time to the first moderate or severe exacerbation, 419 vs. 321 days; hazard ratio, 0.77; 95% CI, 0.64 to 0.93; P = 0.009). Between-group differences in measures of health-related quality of life and symptoms were not significant; thus, no statistical inferences regarding subsequent secondary end points in the statistical testing hierarchy were made. The incidence of adverse events was similar in the mepolizumab and placebo groups. CONCLUSIONS: Treatment with mepolizumab led to a lower annualized rate of moderate or severe exacerbations when added to background triple inhaled therapy among patients with COPD and an eosinophilic phenotype. (Funded by GSK; MATINEE ClinicalTrials.gov number, NCT04133909.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meguro, M., Barley, E. A., Spencer, S., & Jones, P. W. (2007) · Chest · doi:10.1378/chest.06-0702 · Cited by 350
Interleukin-5 in the Pathophysiology of Severe Asthma.
Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G. W., & Heffler, E. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01514 · Cited by 337
Metadata
- Authors
- Sciurba, F. C., Criner, G. J., Christenson, S. A., Martinez, F. J., Papi, A., Roche, N., Bourbeau, J., Korn, S., Bafadhel, M., Han, M. K., Kolterer, S., Miller, K., Mouneimne, D., Fletcher, J., Mayer, B., Min, J., & Pavord, I. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-05
- Volume
- 392
- Issue
- 17
- Pages
- 1710-1720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963258
- Cited by
- 164
- References
- 2
- FWCI
- 97.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. https://app.cochat.ai/papers/10.1056/nejmoa2413181
- The paper
- Sciurba, F. C., Criner, G. J., Christenson, S. A., Martinez, F. J., Papi, A., Roche, N., Bourbeau, J., Korn, S., Bafadhel, M., Han, M. K., Kolterer, S., Miller, K., Mouneimne, D., Fletcher, J., Mayer, B., Min, J., & Pavord, I. D. (2025). Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2413181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.